Fundación Respirar
Fundación Respirar
Av. Cabildo 1548, CABA, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Sergio Pratto
Oscar Luis Rillo
María Cristina Rillo
Maria De Salvo
Christian Fuentes
Claudia Archer
Maria Pamela Llugdar Juri
Ana Isabel Oviedo
Hernan Cartez
Lisset Goncalves
Ana Isabel Oviedo Albor
Open studies
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. - VERITAC-2 - Arvinas Estrogen Receptor, Inc.See more
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment - PfizerSee more
Lung cancer
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer - GlaxoSmithKlineSee more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Cardiovascular disease
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Chronic obstructive pulmonary disease
MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD - Merck Sharp & Dohme LLCSee more
Diabetes
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) - Eli Lilly and CompanySee more
Esophageal cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Gastric cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Gastroesophageal cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Head and neck cancer
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma - JADE - GlaxoSmithKlineSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Kidney cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Liposarcoma
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Lupus
A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy - AMETHYST - BiogenSee more
Obesity
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
Prostate cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Rare diseases
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome - POETYK SjS-1 - Bristol-Myers SquibbSee more
Skin cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Solid tumors
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
